CSPG4 (Chondroitin Sulfate Proteoglycan 4), also known as NG2 or MCSP, is a transmembrane proteoglycan overexpressed in various aggressive cancers, including melanoma, glioblastoma, and triple-negative breast cancer. Its role in tumor progression—promoting cell proliferation, migration, and angiogenesis—has made it a compelling therapeutic target. CSPG4 antibodies are designed to recognize specific epitopes on the extracellular domain of CSPG4. enabling both diagnostic and therapeutic applications.
In research, CSPG4 antibodies are widely used to study tumor biology, particularly in identifying cancer stem cells and mapping tumor microenvironment interactions. Therapeutically, they serve as the foundation for antibody-drug conjugates (ADCs), CAR-T cell therapies, and immune checkpoint blockade combinations. Preclinical studies highlight their ability to inhibit tumor growth and metastasis by blocking CSPG4-mediated signaling pathways or delivering cytotoxic payloads directly to cancer cells.
Despite promise, challenges remain. CSPG4 expression in normal tissues (e.g., pericytes, oligodendrocyte precursors) raises concerns about off-target effects. Advances in antibody engineering, such as humanization and affinity optimization, aim to enhance specificity and reduce immunogenicity. Clinical trials targeting CSPG4 in melanoma and sarcoma are ongoing, with early data suggesting tolerability and anti-tumor activity. Overall, CSPG4 antibodies represent a versatile tool bridging cancer biology insights and translational oncology innovation.